125 related articles for article (PubMed ID: 36622852)
1. BET-HDAC Dual Inhibitors for Combinational Treatment of Breast Cancer and Concurrent Candidiasis.
Huang Y; Liu N; Pan Z; Li Z; Sheng C
J Med Chem; 2023 Jan; 66(2):1239-1253. PubMed ID: 36622852
[TBL] [Abstract][Full Text] [Related]
2. Discovery of BRD4-HDAC Dual Inhibitors with Improved Fungal Selectivity and Potent Synergistic Antifungal Activity against Fluconazole-Resistant
Li Z; Huang Y; Tu J; Yang W; Liu N; Wang W; Sheng C
J Med Chem; 2023 Apr; 66(8):5950-5964. PubMed ID: 37037787
[TBL] [Abstract][Full Text] [Related]
3. Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer.
He S; Dong G; Li Y; Wu S; Wang W; Sheng C
Angew Chem Int Ed Engl; 2020 Feb; 59(8):3028-3032. PubMed ID: 31943585
[TBL] [Abstract][Full Text] [Related]
4. Novel Carboline Fungal Histone Deacetylase (HDAC) Inhibitors for Combinational Treatment of Azole-Resistant Candidiasis.
Li Z; Tu J; Han G; Liu N; Sheng C
J Med Chem; 2021 Jan; 64(2):1116-1126. PubMed ID: 33356256
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
Huang Y; Dong G; Li H; Liu N; Zhang W; Sheng C
J Med Chem; 2018 Jul; 61(14):6056-6074. PubMed ID: 29940115
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors.
Shao M; He L; Zheng L; Huang L; Zhou Y; Wang T; Chen Y; Shen M; Wang F; Yang Z; Chen L
Bioorg Med Chem Lett; 2017 Sep; 27(17):4051-4055. PubMed ID: 28765013
[TBL] [Abstract][Full Text] [Related]
7. Heat shock protein 90 (Hsp90)/Histone deacetylase (HDAC) dual inhibitors for the treatment of azoles-resistant Candida albicans.
Li C; Tu J; Han G; Liu N; Sheng C
Eur J Med Chem; 2022 Jan; 227():113961. PubMed ID: 34742014
[TBL] [Abstract][Full Text] [Related]
8. Development of Potent Dual BET/HDAC Inhibitors via Pharmacophore Merging and Structure-Guided Optimization.
Bauer N; Balourdas DI; Schneider JR; Zhang X; Berger LM; Berger BT; Schwalm MP; Klopp NA; Siveke JT; Knapp S; Joerger AC
ACS Chem Biol; 2024 Feb; 19(2):266-279. PubMed ID: 38291964
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Novel Fedratinib-Based HDAC/JAK/BRD4 Triple Inhibitors with Remarkable Antitumor Activity against Triple Negative Breast Cancer.
Zhao C; Zhang Y; Zhang J; Li S; Liu M; Geng Y; Liu F; Chai Q; Meng H; Li M; Li J; Zheng Y; Zhang Y
J Med Chem; 2023 Oct; 66(20):14150-14174. PubMed ID: 37796543
[TBL] [Abstract][Full Text] [Related]
10. Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer.
Zeng H; Qu J; Jin N; Xu J; Lin C; Chen Y; Yang X; He X; Tang S; Lan X; Yang X; Chen Z; Huang M; Ding J; Geng M
Cancer Cell; 2016 Sep; 30(3):459-473. PubMed ID: 27622335
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma.
Zhang X; Zegar T; Weiser T; Hamdan FH; Berger BT; Lucas R; Balourdas DI; Ladigan S; Cheung PF; Liffers ST; Trajkovic-Arsic M; Scheffler B; Joerger AC; Hahn SA; Johnsen SA; Knapp S; Siveke JT
Int J Cancer; 2020 Nov; 147(10):2847-2861. PubMed ID: 32599645
[TBL] [Abstract][Full Text] [Related]
12. Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells.
Borbely G; Haldosen LA; Dahlman-Wright K; Zhao C
Oncotarget; 2015 Oct; 6(32):33623-35. PubMed ID: 26378038
[TBL] [Abstract][Full Text] [Related]
13. Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors.
Zhang Z; Hou S; Chen H; Ran T; Jiang F; Bian Y; Zhang D; Zhi Y; Wang L; Zhang L; Li H; Zhang Y; Tang W; Lu T; Chen Y
Bioorg Med Chem Lett; 2016 Jun; 26(12):2931-2935. PubMed ID: 27142751
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Novel Fungal Lanosterol 14α-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis.
Han G; Liu N; Li C; Tu J; Li Z; Sheng C
J Med Chem; 2020 May; 63(10):5341-5359. PubMed ID: 32347094
[TBL] [Abstract][Full Text] [Related]
15. 4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads.
Schäker-Hübner L; Warstat R; Ahlert H; Mishra P; Kraft FB; Schliehe-Diecks J; Schöler A; Borkhardt A; Breit B; Bhatia S; Hügle M; Günther S; Hansen FK
J Med Chem; 2021 Oct; 64(19):14620-14646. PubMed ID: 34582215
[TBL] [Abstract][Full Text] [Related]
16. Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
Chen J; Li Y; Zhang J; Zhang M; Wei A; Liu H; Xie Z; Ren W; Duan W; Zhang Z; Shen A; Hu Y
Eur J Med Chem; 2021 Jan; 209():112868. PubMed ID: 33077265
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of novel dual BRD4/HDAC inhibitors.
Amemiya S; Yamaguchi T; Hashimoto Y; Noguchi-Yachide T
Bioorg Med Chem; 2017 Jul; 25(14):3677-3684. PubMed ID: 28549889
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Novel Pyrrolo[2,3-
Liang X; Tang S; Liu X; Liu Y; Xu Q; Wang X; Saidahmatov A; Li C; Wang J; Zhou Y; Zhang Y; Geng M; Huang M; Liu H
J Med Chem; 2022 Jan; 65(2):1243-1264. PubMed ID: 33586434
[TBL] [Abstract][Full Text] [Related]
19. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.
Fiskus W; Sharma S; Qi J; Valenta JA; Schaub LJ; Shah B; Peth K; Portier BP; Rodriguez M; Devaraj SG; Zhan M; Sheng J; Iyer SP; Bradner JE; Bhalla KN
Mol Cancer Ther; 2014 May; 13(5):1142-54. PubMed ID: 24435446
[TBL] [Abstract][Full Text] [Related]
20. Chemical Screen Identifies Diverse and Novel Histone Deacetylase Inhibitors as Repressors of NUT Function: Implications for NUT Carcinoma Pathogenesis and Treatment.
Shiota H; Alekseyenko AA; Wang ZA; Filic I; Knox TM; Luong NM; Huang Y; Scott DA; Jones KL; Gokhale PC; Lemieux ME; Cole PA; Kuroda MI; French CA
Mol Cancer Res; 2021 Nov; 19(11):1818-1830. PubMed ID: 34285087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]